Precision BioSciences Inc (NASDAQ:DTIL)

1.57
Delayed Data
As of Jun 28
 -0.20 / -11.30%
Today’s Change
1.11
Today|||52-Week Range
14.38
-78.85%
Year-to-Date
Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD
Jun 28 / Zacks.com - Paid Partner Content
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
Jun 22 / Zacks.com - Paid Partner Content
Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML
Jun 27 / Zacks.com - Paid Partner Content
Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation
Jun 21 / Zacks.com - Paid Partner Content
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
Jun 27 / Zacks.com - Paid Partner Content
Seagen (SGEN) Stock Up on Rumors of Acquisition by Merck
Jun 20 / Zacks.com - Paid Partner Content
ANI (ANIP) Soars 6.2%: Is Further Upside Left in the Stock?
Jun 27 / Zacks.com - Paid Partner Content
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
Jun 20 / Zacks.com - Paid Partner Content
uniQure (QURE) Up on Safety Data From Huntington's Disease Study
Jun 24 / Zacks.com - Paid Partner Content
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study
Jun 17 / Zacks.com - Paid Partner Content
Precision BioSciences' (DTIL) Stock Up This Week: Here's Why
Jun 23 / Zacks.com - Paid Partner Content
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
Jun 16 / Zacks.com - Paid Partner Content
Apellis (APLS) Expands Deal for Targeted Complement Therapies
Jun 23 / Zacks.com - Paid Partner Content